Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$8,000.

  • Seres Therapeutics' Cash from Investing Activities fell 100.01% to -$8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$313,000, marking a year-over-year decrease of 100.22%. This contributed to the annual value of $142.3 million for FY2024, which is 1244.67% up from last year.
  • Seres Therapeutics' Cash from Investing Activities amounted to -$8,000 in Q3 2025, which was up 95.58% from -$181,000 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Cash from Investing Activities ranged from a high of $141.1 million in Q3 2024 and a low of -$20.7 million during Q1 2021.
  • Its 3-year average for Cash from Investing Activities is $13.9 million, with a median of -$34,000 in 2025.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 319.75% in 2021, then skyrocketed by 7,954.37% in 2024.
  • Seres Therapeutics' Cash from Investing Activities (Quarterly) stood at $13.2 million in 2021, then tumbled by 55.06% to $5.9 million in 2022, then crashed by 114.80% to -$877,000 in 2023, then surged by 89.74% to -$90,000 in 2024, then tumbled by 100.01% to -$8,000 in 2025.
  • Its Cash from Investing Activities stands at -$8,000 for Q3 2025, versus -$181,000 for Q2 2025 and -$34,000 for Q1 2025.